2 results
Approved WMORecruiting
Primary (Parts 1 and 2)• To evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab Primary (Part 3)Evaluate safety of reduced mandatory monitoring…
Approved WMORecruiting
Primary:• To Evaluate the safety and tolerability of tarlatamab • Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)Secondary:• Evaluate anti-tumor activity of tarlatamab as assessed by additional measures • Characterize…